Thomas Adès, The Exterminating Angel, Haus für Mozart, Salzburg

The Salzburg Festival publicity office knew that it had a major musical event on its hands. Before the premiere of Thomas Adès's The Exterminating Angel on 28 July 2016, they held a reception for the world's press on a rooftop balcony overlooking the old town (which, in the name of investigative journalism, your intrepid TEMPO correspondent attended). The procession from such genteel surroundings and through the bustling Hofstallgasse into the auditorium, in which bells were already chiming in the orchestral pit and sheep were standing patiently on stage, enacted one of the central themes of the opera: that of the passage from bourgeois respectability (and, let's be frank, privilege) into a world that is less predictable, less explicable

Treatment of Acute Promyelocytic Leukemia with High White Cell Blood Counts.

Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients

Quasi-Likelihood Estimation for Ornstein-Uhlenbeck Diffusion Observed at Random Time Points

2000 Mathematics Subject Classification: 60J60, 62M99.In this paper, we study the quasi-likelihood estimator of the drift parameter θ in the Ornstein-Uhlenbeck diffusion process, when the process is observed at random time points, which are assumed to be unobservable. These time points are arrival times of a Poisson process with known rate. The asymptotic properties of the quasi-likelihood estimator (QLE) of θ, as well as those of its approximations are also elucidated. An extensive simulation study of these estimators is also performed. As a corollary to this work, we obtain the quasi-likelihood estimator iteratively in the deterministic framework with non-equidistant time points.The first and third authors greatly appreciate the support of the Naturel Sciences and Engineering Research Council of Canada for this research

L'impact du cadre réglementaire fédéral de réduction d'émissions de gaz à effet de serre de 2007 sur les choix des sources d'énergie de l'industrie québécoise des pâtes et papiers

Ce mémoire cherche à élucider de combien variera les parts de marché des sources d'énergie consommées par l'industrie des pâtes et papier suite à l'implantation du programme proposé dans le cadre réglementaire fédéral sur les émissions atmosphériques rendu public en avril 2007. Pour ce faire, nous utilisons un modèle économétrique basé sur la fonction Translog. L'implantation de la réglementation fédérale est simulée en considérant différents scénarios de prix pour une tonne d'émissions de gaz à effet de serre (GES). À partir de notre modèle estimé, nous calculons les élasticité-prix de la demande des sources d'énergie considérées et évaluons de combien variera la consommation et les émissions de ces sources d'énergie suite à l'imposition d'un prix sur la tonne de GE

Highly efficient multilayer organic pure-blue-light emitting diodes with substituted carbazoles compounds in the emitting layer

Bright blue organic light-emitting diodes (OLEDs) based on 1,4,5,8,N-pentamethylcarbazole (PMC) and on dimer of N-ethylcarbazole (N,N'-diethyl-3,3'-bicarbazyl) (DEC) as emitting layers or as dopants in a 4,4'-bis(2,2'-diphenylvinyl)-1,1'-biphenyl (DPVBi) matrix are described. Pure blue-light with the C.I.E. coordinates x = 0.153 y = 0.100, electroluminescence efficiency \eta_{EL} of 0.4 cd/A, external quantum efficiency \eta_{ext.} of 0.6% and luminance L of 236 cd/m2 (at 60 mA/cm2) were obtained with PMC as an emitter and the 2,9-dimethyl-4,7-diphenyl-1,10-phenantroline (BCP) as a hole-blocking material in five-layer emitting devices. The highest efficiencies \eta_{EL.} of 4.7 cd/A, and \eta_{ext} = 3.3% were obtained with a four-layer structure and a DPVBi DEC-doped active layer (CIE coordinates x = 0.158, y=0.169, \lambda_{peak} = 456 nm). The \eta_{ext.} value is one the highest reported at this wavelength for blue OLEDs and is related to an internal quantum efficiency up to 20%

Thomas Ades's 'The Exterminating Angel'

Thomas Adès's third opera, The Exterminating Angel, is based closely upon Luis Buñuel's 1962 film El ángel exterminador, in which the hosts and guests at a high-society dinner party find themselves inexplicably unable to leave the dining room. Initial critical response to the opera too often focused on superficial similarities and discrepancies between the two works at the expense of attending to the specifically musical ways in which Adès presented the drama. This article explores the role that repetition plays in the opera, and in particular how repetitions serve both as a means of critiquing bourgeois sensibilities and as a representation of (loss of) will. I conclude by drawing on the work of Deleuze in order to situate the climax of the opera against the notion of the eternal return, highlighting how the music articulates the dramatic failure of the characters to escape

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Pevonedistat; Chronic myelomonocytic leukemiaPevonedistat; Leucemia mielomonocítica crónicaPevonedistat; Leucèmia mielomonocítica crònicaPANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS; n = 324), higher-risk chronic myelomonocytic leukemia (n = 27), or acute myeloid leukemia (AML) with 20% to 30% blasts (n = 103). The primary end point was event-free survival (EFS). In the intent-to-treat population, the median EFS was 17.7 months with pevonedistat+azacitidine vs 15.7 months with azacitidine (hazard ratio [HR], 0.968; 95% confidence interval [CI], 0.757-1.238; P = .557) and in the higher-risk MDS cohort, median EFS was 19.2 vs 15.6 months (HR, 0.887; 95% CI, 0.659-1.193; P = .431). Median overall survival (OS) in the higher-risk MDS cohort was 21.6 vs 17.5 months (HR, 0.785; P = .092), and in patients with AML with 20% to 30% blasts was 14.5 vs 14.7 months (HR, 1.107; P = .664). In a post hoc analysis, median OS in the higher-risk MDS cohort for patients receiving >3 cycles was 23.8 vs 20.6 months (P = .021) and for >6 cycles was 27.1 vs 22.5 months (P = .008). No new safety signals were identified, and the azacitidine dose intensity was maintained. Common hematologic grade ≥3 treatment emergent adverse events were anemia (33% vs 34%), neutropenia (31% vs 33%), and thrombocytopenia (30% vs 30%). These results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of continuing therapy for >3 cycles. The trial was registered on clinicaltrials.gov as #NCT03268954.This study was sponsored by Takeda Development Centers Inc (TDCA; Lexington, MA)

A French translation of the obsessive-compulsive drinking scale for craving in alcohol-dependent patients: a validation study in Belgium, France, and Switzerland

The Obsessive-Compulsive Drinking Scale (OCDS) is an instrument developed to measure cognitive aspects of alcohol craving. The aim of this study was to validate the French translation of the OCDS according to the international methodology as published by Hunt and coworkers (see text), including forward-backward translations, patient interviews (9 patients), patient's perception of acceptability (15 patients), and final validation within a treatment program (50 patients). All 74 patients were native French-speaking alcohol-dependent patients from Belgium, France, and Switzerland. The derived aggregated total (TOT) score and both subscores corresponding to the obsessive (OB) and compulsive (CP) dimensions were shown to be asymptomatically normal. Good internal consistencies were found, with Cronbach alpha: TOT = 0.88; OB = 0. 82; CP = 0.79. The test-retest procedure was used to examine intrarater reliability (r = 0.81). The construct validity was examined with linear correlation of the two main components: r(OB, CP) = 0.62; r(OB, TOT) = 0.86; r(CP, TOT) = 0.92. Principal-components analysis revealed two main factors: the first factor representing the total scale score, while the obsessive and compulsive subscale scores were distributed along factor two. The translated scale seems to be psychometrically as valid as the original English scale and confirms the psychometric properties of the OCDS. [Ed.]]]> eng oai:serval.unil.ch:BIB_F7D93BF6D7F8 2022-05-07T01:30:22Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_F7D93BF6D7F8 Langue, Littérature et Altérité Janz, N. (ed.) Vernand, D. (ed.) info:eu-repo/semantics/book book 1992 fre oai:serval.unil.ch:BIB_F7DA4CD40334 2022-05-07T01:30:22Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_F7DA4CD40334 Landslides and debris-flows: Analysis, monitoring, modeling and hazard assessment Jaboyedoff, M. Crosta, G.B. Arattano, M. Jaboyedoff, M. (ed.) Crosta, G.B. (ed.) Arattano, M. (ed.) info:eu-repo/semantics/book book 2005 eng oai:serval.unil.ch:BIB_F7DA82AC327E 2022-05-07T01:30:22Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_F7DA82AC327E Doit-on modifier le traitement anticoagulant avant des extractions dentaires? [Dental extractions in patients taking anticoagulants: is alteration of the anticoagulant regime necessary?] info:eu-repo/semantics/altIdentifier/pmid/15997980 Madrid, C. info:eu-repo/semantics/review article 2005 Revue Médicale Suisse, vol. 1, no. 21, pp. 1418, 1421-1422, 1424 info:eu-repo/semantics/altIdentifier/pissn/1660-9379 <![CDATA[A major concern in the management of patients under anticoagulants is the potential for excessive bleeding after dental procedures. Recommendations for the administration of oral anticoagulants in conjunction with oral surgery range from complete withdrawal of anticoagulants to the maintenance of an unchanged therapy. Rising evidences show that the alteration of anticoagulation is not necessary for patients with INR of 4 or less previous to tooth extractions. Topical antifibrinolytics as tranexamic acid control successfully alveolar bleeding. It is time to stop interrupting anticoagulant therapy for oral surgery. A theoretical risk of hemorrhage after dental surgery in patients at therapeutic levels of anticoagulation exists but it is minimal and is greatly overweighed by the risk of thromboembolism after alteration of the anticoagulant therapy

Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia

Since the successful introduction of all-trans-retinoic acid (ATRA) and its combination with anthracycline-containing chemotherapy, the prognosis for acute promyelocytic leukemia (APL) has markedly improved. With ATRA and anthracycline-based-chemotherapy, the complete remission rate is greater than 90%, and the long-term survival rate is 70-89%. Moreover, arsenic trioxide (ATO), which was introduced for APL treatment in 1994, resulted in excellent remission rates in relapsed patients with APL, and more recently, several clinical studies have been designed to explore its role in initial therapy either alone or in combination with ATRA. APL is a rare disease in children and is frequently associated with hyperleukocytosis, which is a marker for higher risk of relapse and an increased incidence of microgranular morphology. The frequency of occurrence of the promyelocytic leukemia/retinoic acid receptor-alpha (PML/RARα) isoforms bcr 2 and bcr 3 is higher in children than in adults. Although recent clinical studies have reported comparable long-term survival rates in patients with APL, therapy for APL in children is challenging because of the risk of early death and the potential long-term cardiac toxicity resulting from the need to use high doses of anthracyclines. Additional prospective, randomized, large clinical trials are needed to address several issues in pediatric APL and to possibly minimize or eliminate the need for chemotherapy by combining ATRA and ATO. In this review article, we discuss the molecular pathogenesis, diagnostic progress, and most recent therapeutic advances in the treatment of children with APL